Infectious Diseases | Novartis

Press Release
Aug 28, 2023

Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Press Release
Jan 24, 2023

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Press Release
Nov 07, 2022

Sandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibiotics
Story
Jun 23, 2022

Renewing our commitment to neglected tropical disease and malaria elimination
Press Release
Jun 23, 2022

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Story
Apr 19, 2022

Staying one step ahead of the malaria parasite
Story
Apr 07, 2022

Tackling the health toll of climate change
Story
Apr 14, 2021

Bringing Chagas disease to people’s attention
Press Release
Mar 04, 2021

Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
Press Release
Dec 14, 2020

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19
Press Release
Oct 28, 2020

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19
Story
Aug 21, 2020

Building collaborations to fight a pandemic